PUBLIC EXPENDITURE ON AUTHORISED ORPHAN DRUGS IN THE CZECH REPUBLIC BETWEEN 2008 AND 2013

被引：0
|
作者：
Vocelka, M. [1 ]
Spurna, M. [1 ]
Fuksa, L. [2 ]
Hambalek, J. [1 ]
机构：
[1] State Inst Drug Control, Prague, Czech Republic
[2] Charles Univ Prague, Fac Pharm, CS-50165 Hradec Kralove, Czech Republic
来源：
VALUE IN HEALTH | 2014年 / 17卷 / 07期
关键词：
D O I：
10.1016/j.jval.2014.08.1657
中图分类号：
F [经济];
学科分类号：
02 ;
摘要：
PSY27
引用
收藏
页码：A526 / A526
页数：1
相关论文
共 41 条
  • [1] AVAILABILITY AND REIMBURSEMENT OF ORPHAN DRUGS IN THE CZECH REPUBLIC
    Ornstova, E.
    Sebestianova, M.
    Paris, M.
    Mlcoch, T.
    Bartakova, J.
    Chadimova, K.
    Hajickova, B.
    Dolezal, T.
    [J]. VALUE IN HEALTH, 2018, 21 : S461 - S461
  • [2] PRICING AND REIMBURSEMENT SYSTEM OF ORPHAN DRUGS IN THE CZECH REPUBLIC
    Prochazkova, M.
    Kubickova, P.
    Mazelova, J.
    Hambalek, J.
    Heislerova, M.
    [J]. VALUE IN HEALTH, 2013, 16 (07) : A474 - A474
  • [3] Innovation Activities of Public Organizations in the Czech Republic between 2008 and 2014
    Vokoun, Marek
    [J]. CURRENT TRENDS IN PUBLIC SECTOR RESEARCH, 2019, : 228 - 236
  • [4] Quality of Public Finance and Government Expenditure in the Czech Republic
    Szarowska, Irena
    [J]. PROCEEDINGS OF THE 15TH INTERNATIONAL CONFERENCE ON FINANCE AND BANKING, 2016, : 375 - 384
  • [5] Public Procurement Construction Contracts in the Czech Republic between 2006-2013
    Dufek, Lubos
    [J]. PROCEEDINGS OF THE 19TH INTERNATIONAL CONFERENCE: THEORETICAL AND PRACTICAL ASPECTS OF PUBLIC FINANCE 2014, 2014, : 38 - 45
  • [6] THE IMPACT OF SOCIAL EXPENDITURE ON PUBLIC DEBT IN THE CZECH REPUBLIC AND SLOVAKIA
    Raisova, Manuela
    Pavlikova, L'udmila
    Semancikova, Jozefina
    [J]. E & M EKONOMIE A MANAGEMENT, 2016, 19 (03): : 158 - 172
  • [7] The impact of changes in national prescribing conditions for statins on their public expenditure and utilization in the Czech Republic 1997-2013
    Fuksa, Leos
    Vocelka, Milan
    Vytrisalova, Magda
    [J]. HEALTH POLICY, 2015, 119 (09) : 1255 - 1264
  • [8] EXPENDITURES AND AVAILABILITY OF ORPHAN DRUGS IN THE CZECH REPUBLIC: SEVEN YEAR EXPERIENCE (2004-2010)
    Klimes, J.
    Dolezal, T.
    Vocelka, M.
    Suchankova, E.
    Kruntoradova, K.
    [J]. VALUE IN HEALTH, 2012, 15 (07) : A434 - A434
  • [9] Analysis of the Development of the Public Procurement in the Czech Republic in the Years 2008-2015
    Chmelova, Pavla
    Stipek, Vladimir
    [J]. POLITICKA EKONOMIE, 2017, 65 (03) : 316 - 334
  • [10] Highly innovative drugs in the Czech Republic: retrospective analysis of impact on early market entry, regular reimbursement system entry and public pharmaceutical expenditure
    Anna Lukačišinová
    Helena Skácelová
    [J]. Journal of Pharmaceutical Policy and Practice, 8 (Suppl 1)
12345